Efficacy of Nano-curcumin Supplementation on Depression, Anxiety, Stress and Clinical Symptoms in Migraine Patients: A Randomized Double-blind Clinical Trial
Abstract
Migraine is a debilitating neuroinflammatory disorder. Patients
with migraine often experience elevated levels of depression, anxiety, and stress, which are
associated with the frequency and severity of migraine attacks. Curcumin has been shown
to have regulatory effects on depression, anxiety, and stress, as well as analgesic properties
through various mechanisms. The objective of this study was to assess the impact of nanocurcumin
supplementation on depression, anxiety, stress, and clinical manifestations in
patients with migraine.
This study was conducted as a randomized, double-blind clinical trial. A
total of forty-four patients with episodic migraines were recruited for the trial. Stratified
randomization was employed to ensure a balanced distribution of participants based on
BMI and sex. The patients were equally assigned to two groups using permuted block randomization:
1) the intervention group, which received 80 mg of nano-curcumin, and 2) the
placebo (control) group, which received a paraffin-based placebo. The intervention and
control periods lasted for 2 months. Anthropometric and demographic data, clinical signs
and symptoms (including headache frequency, duration, and severity as reported by the
patients), as well as stress, anxiety, and depression scores (using the Dass-21 questionnaire),
were recorded before and after the study. The collected data were analyzed using
SPSS 22. For normally distributed data, paired t-tests and independent t-tests were…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.